Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Honghua Xiaoyao Tablet for Premenstrual Syndrome
ChiCTR2300071827Phase 4Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine East Hospital
- Start
- May 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of honghua xiaoyao in premenstrual syndrome (PMS) (2 arms), sponsored by Beijing University of Chinese Medicine East Hospital. Primary endpoint: Change in DRSP total score after 3 menstrual cycles vs baseline. Planned start May 2023; status: not yet recruiting.
02
Drugs
honghua xiaoyao
03
Conditions
premenstrual syndrome (PMS)
Beyond the preview
Go deeper on ChiCTR2300071827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071827.